PTN - Palatin starts Phase 2 obesity study of bremelanotide with Zepbound June, 12 2024 10:27 AM Palatin Technologies Inc. 2024-06-12 10:27:30 ET More on Palatin Tech Palatin Technologies, Inc. (PTN) Q3 2024 Earnings Call Transcript Palatin Tech GAAP EPS of -$0.53 misses by $0.03 Palatin Tech Q3 2024 Earnings Preview Seeking Alpha’s Quant Rating on Palatin Tech Historical earnings data for Palatin Tech For further details see: Palatin starts Phase 2 obesity study of bremelanotide with Zepbound